Johnson & Johnson Unleashes Kenvue: Tylenol to Neutrogena, $40B Revenue Unit Spinoff Preps for IPO Blitz
None Johnson & Johnson (NYSE: JNJ) is reportedly readying an investor roadshow to pitch shares of its consumer-healthcare spinoff business, dubbed Kenvue, as…
Source: biztoc.com